How Common Is Diarrhoea During Treatment Diarrhoea was reported in a dose-dependent manner in Phase 2 trials
Hurtado I, Robles C, Peir S, Garca-Sempere A, Sanflix-Gimeno G
Nat Med 2013 , 19 , 576585
Randomized controlled trials of AOMs conducted in population for at least 4 weeks and followed for 4 or more weeks after discontinuation were included
Key risks include worsened gastrointestinal side effects (nausea, vomiting), hypoglycaemia (particularly in patients taking insulin or sulfonylureas), dehydration, inadequate nutritional intake, and potential exacerbation of pancreatitis or gallbladder problems
Theyre not FDA-approved and are prepared according to a prescription for an individual patient